All In Biotech

Drug Trial Radar · NCT01945775

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE

Last checked: Nov 19, 2026Latest source record: Jan 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 431 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

431

Actual

Start

Oct 14, 2013

Primary completion

Sep 15, 2017

Study completion Mar 5, 2021

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Medivation, Inc.
First posted
Sep 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.

Conditions

  • Breast Neoplasms
  • BRCA 1 Gene Mutation
  • BRCA 2 Gene Mutation

Interventions

  • talazoparibDrug

    Until progression or unacceptable toxicity develops

  • Physician's-ChoiceDrug

    Capecitabine, Eribulin, Gemcitabine or Vinorelbine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS): Independent Radiological Facility (IRF) AssessmentTime frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)

Locations

362 sites in 16 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates P.C. - NAHOA

    Flagstaff, Arizona

  • HonorHealth

    Scottsdale, Arizona

  • Virginia G. Piper Cancer Pharmacy

    Scottsdale, Arizona

  • Kaiser Permanente Medical Center Lab Drawing Station

    Antioch, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Antioch, California

  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center

    Bakersfield, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Fairfield, California

  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare

    Fullerton, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Gilroy, California

  • Los Angeles Hematology Oncology Medical Group

    Glendale, California

  • Los Angeles Hematology Oncology Medical Group

    Glendale, California

  • Marin Specialty Care

    Greenbrae, California

  • Los Angeles Hematology Oncolgy Medical Group

    Los Angeles, California

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • Drug Management Only: UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D.

    Los Angeles, California

  • Drug Management only: UCLA West Medical Pharmacy

    Los Angeles, California

  • UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm. D.

    Los Angeles, California

  • UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D.

    Los Angeles, California

  • UCLA West Medical Pharmacy, Attn: Steven L. Wong

    Los Angeles, California

  • UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D.

    Los Angeles, California

  • Regulatory Managment Only: TRIO-US Central Administration

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • TRIO-US Central Administration

    Los Angeles, California

  • UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D.

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Martinez, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Milpitas, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Modesto, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Mountain View, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Napa, California

  • Kaiser Permanente Medical Center (clinic+DSL)

    Oakland, California

  • Kaiser Permanente Medical Center (Radiology)

    Oakland, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Pleasanton, California

  • Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer care Associates

    Redondo Beach, California

  • Kaiser Permanente Medical Center Lab Drawing Station

    Redwood City, California

  • Kaiser Permanente Medical Center (clinic+DSL)

    Roseville, California

  • Southern California Permanente Medical Group

    San Diego, California

  • UCSF - Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • UCSF Helen Diller Comprehensive Cancer Centre - Precision Cancer Medicine Building

    San Francisco, California

  • Kaiser Permanente Mission Bay Medical Center Lab Drawing Station

    San Francisco, California

Showing 40 of 362 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.